Reduced DNA repair capability is associated with developing lung cancer, especially in nonsmokers. XPC participates in the initial recognition of DNA damage during the DNA nucleotide excision repair process. We hypothesize that inactivation of XPC by promoter hypermethylation may play an important role in the reduction of DNA repair capability to cause p53 mutation during lung carcinogenesis. In this report we demonstrate that hypermethylation of 17 CpG islands between À175 and À1 of the XPC promoter correlates very well with XPC expression levels in eight lung cancer cell lines. When cells with hypermethylated XPC promoters were treated with the demethylating agent 5-aza-2 0 -deoxycytidine, XPC expression was de-repressed. Interestingly, XPC hypermethylation was found in 4 of 5 (80%) lung cancer cell lines harbored p53 mutation, but not observed in two lung cancer cells which had a wild-type p53 gene. Among the analysis of the hypermethylation status of 158 lung tumors, XPC hypermethylation is more common in nonsmokers (39 of 94, 41%) than in smokers (14 of 64, 22%; P ¼ 0.010). Additionally, XPC hypermethylation is more often with G-T or G-C mutations in the p53 gene. To verify whether XPC inactivation is involved in the occurrence of p53 mutation, XPC gene of A549 cells was knockdown by a small interference RNA and then XPC-inactivated cells were treated with benzo[a]pynrene for different passages. Surprisingly, G-T mutation in p53 gene at codon 215 was indeed detected in XPCinactivated A549 cells of passages 15 and confirmed by loss of transcription activity of mdm2. These results show that hypermethylation of the XPC promoter may play a crucial role in XPC inactivation, which may partly contribute to the occurrence of p53 mutations during lung tumorigenesis, especially nonsmokers.
Introduction
Lung cancer is the leading cause of cancer deaths worldwide. Lung cancer patients have a lower DNA repair capacity than healthy subjects, and nonsmokers have a lower DNA repair capacity than smokers (Wei et al., 2000; Bosken et al., 2002; Shen et al., 2003; Neumann et al., 2005) . Thus, DNA repair may be more frequently inactivated in nonsmoking lung cancers than smoking lung cancers, and defective repair may contribute to lung tumorigenesis, especially in nonsmokers. Seven human genes, xeroderma pigmentosa (XP) XPA through XPG, have been identified as essential for nucleotide excision repair (NER). XPC is a subunit of the NER multi-protein machinery that facilitates DNA damage recognition (Friedberg, 2001; Riedl et al., 2003) . An in vitro study suggested that binding of XPC to damaged DNA is the rate-limiting step for NER (Janicijevic et al., 2003; Tapias et al., 2004) . Accumulated evidence also indicates that genetic polymorphisms of DNA repair genes such as XPA, XPC and ERCC1 are associated with increased risk of lung cancer (Mellon et al., 2002; Park et al., 2002; Marin et al., 2004; Hu et al., 2005; Suk et al., 2005) . XPC gene knockout mice are highly predisposed to skin cancer after exposure to ultraviolet B (UVB) radiation (Sands et al., 1995) and to liver and lung cancers after treatment with either 2-acetylaminofluorene (AAF) or its activated derivative, N-hydroxy-2-AAF (Cheo et al., 1999; Inga et al., 2002) . The allelic loss of XPC observed in some human lung tumors, coupled with a high incidence of lung tumors in XPC À/À mice, suggests that XPC allelic loss may be an early event in human lung tumorigenesis (Hollander et al., 2005) .
XPC expression is positively regulated by p53, and the XPC promoter contains a p53 response element (Adimoolam and Ford, 2002) . However, our initial study showed a wide range of XPC messenger RNA (mRNA) levels expressed in lung cancer cell lines that did not express functional p53. Moreover, we also found XPC mRNA expression was also detected in lung tumors from non-small cell lung cancer (NSCLC) patients who had a p53 mutation. These observations prompted us to investigate whether a defect in epigenetic regulation of the XPC promoter region is involved in XPC gene inactivation apart from transcriptional regulation through p53.
Repair enzyme activities can be altered by genetic polymorphisms, such as the Lys751Gln XPD polymorphism and the XRCC1 polymorphism Arg3999Gln, which increase the occurrence of p53 mutations in lung cancer (Ryk et al., 2006) . However, XPC polymorphisms have not been associated with p53 mutations in human cancers. Interestingly, in mice, homozygous XPC mutations in a heterozygous Trp53 background caused additional mutations in the Trp53 gene upon induction by UVB (Nahari et al., 2004) . Additionally, p53 mutations are frequently found in skin melanomas of XP patients (Alain et al., 2001; Azzam et al., 2002) . Therefore, inactivation of the XPC gene may impair DNA repair capacity that in turn increases mutation frequency, leading to an accumulation of mutations in p53.
Here, we reveal an epigenetic mechanism whereby hypermethylation plays an important role in regulating XPC expression, and silencing XPC expression might increase the occurrence of p53 mutations in lung cancer. Our results suggest that XPC inactivation through promoter methylation occurs more often in nonsmokers with lung cancer.
Results

Silencing of XPC via promoter hypermethylation
To characterize the XPC promoter, a fragment spanning positions À2536 to À1 relative to the XPC transcription start site was amplified by polymerase chain reaction (PCR), sequenced and cloned into a luciferase reporter plasmid. A series of XPC promoter constructs with various deletions, as shown in Figure 1a , were individually co-transfected with pCDNA or pCDNA-p53 into p53 null H1299 lung cancer cells. The expression of P53 was confirmed by Western-blot analyses (data not shown). The luciferase activity of the p1174, p574 and p385 promoter fragment transfectants was over 70% of that of the full-length promoter p2536 transfectant in both cells. These results would not be the effect of cytotoxicity induced by transfection as all constructs were transiently expressed in this study. Although deletion of the region between À2536 and À1174 that contained a putative p53-responsive element reduced promoter activity, the degree of reduction was similar in H1299 cells with and without p53 (Figure 1b) . Nevertheless, more than 60% of luciferase activity remained in the shortest promoter construct most proximal to the transcription start site, p175, in both cells. These results indicate that the promoter region of XPC between À175 and À1 might play an important role in regulating XPC transcription in H1299 lung cancer cells independently of p53.
The promoter region between À175 and À1 of XPC contains two putative AP1-binding sites and two GCbox/SP1 transcription factor-binding elements, as predicted by the TRANSFAC program ( Figure 1c ). Additionally, the EMBOSS program detected 17 CpG islands within this region. Therefore, hypermethylation of CpG islands within the À175/À1 promoter region might contribute to the regulation of XPC transcription. To examine whether this region could attenuate transcription upon hypermethylation, p175 was methylated with SssI methylase and transfected into H1299 cells. Luciferase activity was almost nil in these cells (Figure 1c ), suggesting that hypermethylation of the À175/À1 promoter region might be a very important mechanism by which XPC transcription is regulated.
The role of p53 and promoter hypermethylation in silencing XPC in vivo It has been shown that the XPC promoter region contains the p53 response element, and functional p53 is required for XPC expression in HCT116 colon cancer cells (Adimoolam and Ford, 2002) . In this study, the luciferase activities of various promoter deletion constructs were two-to threefold higher in H1299 cells expressing wild-type p53 than in H1299 cells alone (data not shown). However, deletion of the putative p53-responsive element between À2536 and À1174 did not dramatically decrease the effect of p53 on luciferase activity. To further elucidate the role of p53 in lung cancer, XPC mRNA levels were examined in six lung cancer cell lines carrying p53 mutations, H1299 (p53 null), Calu-1 (R280K), H1355 (E285K), H23 (M246I), H441 (R158L) and H661 (S215I), and two lung cancer cell lines with wild-type p53 (A549 and CH27). As expected, XPC mRNA expression was higher in A549 and CH27 cells with normal p53 expression (Figure 1d ). However, XPC mRNA expression varied widely among strains carrying mutated p53; the expression was quite high in H23 cells, less in H1299 and H661 cells and nil in Calu-1, H1355 and H441 cells (Figure 1d) . A similar finding in various lung cancer cells was also observed in XPC protein expression levels ( Figure 1d ). These results strongly suggest that mechanisms other than p53 activation regulate XPC transcription in lung cancer cells. Because in vitro methylation of CpG islands located in the region of À175 to À1 of the XPC promoter silenced reporter gene expression (Figure 1c) , we examined whether XPC mRNA levels in cancer cells correlated with the hypermethylation status of the XPC promoter as assessed by bisulfite sequencing. Upon sodium bisulfite treatment, unmethylated cytosines are converted into uracil and the uracils are detected by sequencing of the PCR-amplified region of interest. For cell lines lacking XPC mRNA -Calu-1, H1355 and H441 -the CpG islands within 175 bp of the XPC promoter were mostly hypermethylated (Figure 2a ). Less XPC mRNA was observed in H661 cells, and the XPC promoter was methylated on about half (8 of 17) of the CpG islands. Only two to four of the 17 CpG islands were methylated in CH27, H1299 and H23 cells, which expressed high levels of XPC, and no CpG methylation was detected in the XPC promoter of A549 cells, which expressed the highest level of XPC (Figure 2b ). Additionally, there are 13 CpG islands in exon 1 of XPC gene (Nos. 18-30 CpG islands). About 40% of the CpG islands (Nos. 26-30 CpG islands) were methylated in Calu-1, H1355, H441 and H661 cells, not in A549, CH27 and H1299 cells (Figure 2a) . The hypermethylation status of CpG islands in exon 1 was mostly concurrent with the status of CpG islands methylation at promoter region except for H23 cells. As the expression of XPC is correlated better with the status of methylation at promoter region than at exon 1 in tested cell lines, we consider that hypermethylation of CpG islands at promoter region may play more important role in XPC transcription silencing.
The promoter hypermethylation of Calu-1, H1355, H441 and H661 cells was confirmed by methylationspecific PCR (MSP) (including 4, 5, 6, 7, 15, 16 and 17 CpG islands), and consistently hypermethylation was not observed in H1299, H23, CH27 and A549 cells (Figure 2b ). Two HpaII restriction enzyme recognition sites are located at the 10th and 15th CpG islands within the À175/À1 region of XPC (Figure 1c ). XPC promoter hypermethylation in Calu-1, H1355, H441 and H661 cells was further confirmed by HpaII-based PCR (Figure 2b ). To clarify whether promoter hypermethylation contributes to XPC transcriptional silencing, Calu-1 and H441 cells were treated with a demethylating agent, 5-aza-dC, and then analysed by real-timepolymerase chain reaction (RT-PCR) to determine XPC mRNA levels. As shown in Figure 2c , demethylation of the XPC promoter in Calu-1 and H441 cells derepressed XPC mRNA expression, and the degree of derepression correlated positively with the 5-aza-dC dose. Taken together, these data clearly demonstrate that hypermethylation of the À175/À1 promoter region of XPC is responsible for transcriptional silencing in Calu-1 and H441 lung cancer cells.
Occurrence of p53 mutation in XPC knockdown A549 lung cancer cells A recent knockout mice study indicated that XPC inactivation leads to lung tumors and is associated with early event in human lung carcinogenesis (Hollander et al., 2005) , and it further suggested that XPC inactivation coupled with cigarette smoking or other environmental carcinogens would lead to additional mutations in genes, such as p53 that are frequent targets in lung cancer (Hollander et al., 2005) . In this study, we found 4 of 5 tested lung cancer cells harbored p53 missense mutations had XPC hypermethylation, but two lung cancer cell lines with wild-type p53 did not have XPC hypermethylation. Thus, we hypothesized that XPC inactivation in above cell lines may lead to the occurrence of p53 mutation. To verify whether XPC inactivation was associated with the occurrence of p53 mutation, the RNA interference (RNAi) technique was used to knockdown XPC gene expression and the cells were treated with benzo[a]pyrene (BaP) for 15 passages to detect whether p53 mutation may occur in XPC knockdown lung cancer cells. As shown in Figure 3a , XPC protein expression was significantly diminished in six XPC knockdown A549 stable clones as compared with that of A549 parental cells. These six clones and vector control cells were continuously treated with 1 mM BaP and direct sequence analyses were performed to analyse exons 5-8 of the p53 gene at passages 3, 6, 9, 12 and 15. Surprisingly, 2 of 6 XPC knockdown cells of passage 15 were detected with G-T mutations in p53 gene at codon 215 (p53 mutant S215I) (Figure 3b ), and p53 mutation was not found in vector control cells (data not shown). To examine transcriptional activity of p53 mutant S215I, H1299 cells were transfected by a plasmid containing the wild-type p53 or p53 mutant S215I along with a luciferase reporter construct controlled by mdm2 promoter containing a p53-responsive element (pGL3-mdm2-p53 RE luc). As expected, mdm2 promoter was transactivated by wild-type p53, whereas the transcriptional activity of p53 mutant S215I was completely diminished (Figure 3c ). This result further confirms that p53 mutation occurred in XPC knockdown cells after BaP treatment.
Association of XPC promoter hypermethylation with XPC expression in lung cancer patients As the hypermethylation status of the XPC promoter strongly correlated with the XPC mRNA levels in the lung cancer cell lines, we next explored whether this relationship is present in lung cancer patients. Hypermethylation of the XPC promoter in tumor cells of lung cancer patients was analysed by HpaII-based PCR and partly further confirmed by direct sequencing. Figure 4a and b shows representative examples of lung tumor XPC hypermethylation as assayed by the two methods. Of the 158 tumors analysed, 53 (34%) showed hypermethylation in the XPC promoter. Interestingly, such hypermethylation was more common in nonsmokers (39/94, 41%) than in smokers (14/64, 22%; P ¼ 0.010) (Table 1) , without any correlation in the studied clinicopathogical parameters, which included age, tumor stage, tumor size and nodal micrometastasis (Table 1) .
To understand whether hypermethylation is responsible for XPC transcriptional silencing in lung cancer 0 -aza-dC (1 or 10 mM) for 5 days. XPC mRNA levels were analysed by RT-PCR. 18S rRNA was used as an internal control; b: methylation status of the 10th and 15th CpG island of the XPC promoter in lung cancer cell lines after treatment with 1 or 10 mM 5-aza-dC for 5 days was analysed by HpaII-based PCR. Products were obtained only if the target sequence was methylated at the HpaII site (I, PCR after HpaII digestion; II, PCR without a prior HpaII digestion; U, untreated; S, PBS solvent; 1, 1 mM 5 0 -aza-dC; 10, 10 mM 5 0 -aza-dC; Control, A549 cells as a positive control; Blank, no cDNA control; M, molecular marker).
Association of XPC promoter methylation with p53 mutations Y-H Wu et al patients, XPC mRNA and protein expression were determined by RT-PCR and immunohistochemistry, respectively. Figure 4b and c shows representative XPC mRNA and protein expression data, respectively. The hypermethylation status of the XPC promoter correlated very well with gene expression, in that XPC mRNA expression correlated negatively with XPC promoter hypermethylation (Po0.001), and XPC protein expression correlated positively with XPC mRNA (Po0.001) in lung tumors (Table 2) . These results clearly indicate that XPC gene inactivation is regulated predominantly by promoter hypermethylation in lung cancer patients.
Association of XPC promoter hypermethylation with p53 mutation in lung cancer patients p53 mutations occur frequently in lung cancers. Although our results suggest that hypermethylation is one of the major mechanisms that regulate the expression of the XPC gene, p53 also influences XPC expression in cancer cell lines. The p53 gene was sequenced in the 158 lung specimens whose XPC mRNA levels were measured. Of 99 cases with wild-type p53, 49 (49%) expressed XPC, whereas 50 (51%) did not, as determined by RT-PCR (Table 2 ). This result suggests that another mechanism(s) could act as a superior regulator over p53, or in conjunction with p53, to regulate XPC. Interestingly, a higher frequency of mutated p53 was observed in cases where XPC was inactivated. Of the 59 patient tumors with p53 mutations, 46 (78%) did not express XPC, whereas 13 (22%) did (Table 2) . Therefore, we further examined whether XPC promoter hypermethylation correlated with mutated p53 in lung cancer patients. Of the 59 cases with p53 mutations, 25 (42%) showed hypermethylation in the XPC promoter, whereas of the 99 samples with wildtype p53, 28 (28%) had a hypermethylated XPC promoter (Table 1) . Therefore, hypermethylation of the XPC promoter is associated with p53 mutations, but the association did not reach statistical significance (P ¼ 0.070, Table 1 ). As mentioned above, XPC inactivation was predominately regulated through promoter hypermethylation, especially in nonsmokers (Table 2) . We further examine the association between XPC protein expression and p53 mutations in lung cancer patients with different smoking statuses (Table 3) . In nonsmokers, lung tumors without XPC protein expression had higher frequency of p53 mutation than those with XPC protein expression (P ¼ 0.010), whereas this association was not observed in smokers (P ¼ 0.793). These results clearly suggest that XPC inactivation by promoter hypermethylation could increase the occurrence of p53 mutation in lung cancer patients, especially in nonsmokers.
The above results indicate a strong correlation between p53 mutations and hypermethylation of the XPC promoter. Hypermethylation of O 6 -methylguanine-DNA methyltransferase (MGMT) has been shown to correlate with a G:C to A:T mutation pattern in p53 (Esteller et al., 2000; Wolf et al., 2001; Zhang et al., 2003) . We thus determined whether p53 mutation patterns likewise shifted due to XPC hypermethylation; all 59 cases with p53 mutations were examined in this regard. The results showed that 69% (11 of 16) of the tumors with G-T or G-C mutations in the p53 gene also presented XPC promoter hypermethylation, compared with 33% (14 of 43) of tumors with other p53 mutation patterns (P ¼ 0.012) or 27% (28 of 99) of tumors with wild-type p53 (P ¼ 0.002) (Figure 4d ) that were associated with XPC hypermethylation. Moreover, when tumors with XPC hypermethylation were examined, about 21% (11 of 53) contained G-T or G-C mutations in p53 (Figure 4d ). In contrast, only 4% (5of 105) of G-T or G-C p53 mutations were observed in tumors with an unmethylated XPC promoter (P ¼ 0.012) (Figure 4d ). On the other hand, no difference in the frequencies of p53 mutation patterns (data not shown), other than G-T or G-C, was observed between unmethylated and hypermethylated tumors (G-T, 9% versus 28%, P ¼ 0.007; G-C, 6% versus 16%, P ¼ 0.047).
Discussion
This study demonstrates that hypermethylation plays an important role in regulating XPC gene expression. A promoter deletion construct containing the region from À175 to À1 of the XPC promoter retained 60% of luciferase reporter activity, suggesting that this region contains cis elements involved in regulating XPC expression. This region is predicted to contain 17 CpG islands and two putative SP1 and AP1 sites. The SP1 sites overlap with the 5th and 10th CpG islands, and the AP1 sites are located at the 7th and 15th CpG islands. The 10th and 15th CpG islands are also recognized by HpaII. As evaluated by HpaII restriction digestion, XPC hypermethylation correlates with XPC mRNA expression in lung tumors, supporting the idea that SP1-and AP1-binding sites at the 10th and 15th CpG islands, respectively, may play an important role in XPC transcription. On the other hand, XPC mRNA expression was not influenced by methylation of the first, second, third, or 17th CpG island in H1299 and H23 lung cancer cell lines (Figure 2a and b) , in agreement with the lack of predicated transcription factor sites in those CpG islands. Additionally, all CpG islands overlapping with the two SP1 sites and two AP1 sites were methylated in H661 cells (with low XPC expression), except for the 7th CpG island within an AP1 site (Figures 1c, 2a and b) . These findings strongly support the role of hypermethylation of CpG islands containing AP1-and SP1-binding sites in XPC transcription. It was previously reported that the region between À2536 and À1175 of the XPC promoter contains a p53-responsive element that upregulates XPC expression (Adimoolam and Ford, 2002) . However, in our study, deletion constructs that lacked this region did not dramatically reduce promoter activity. This discrepancy may be due to the fact that, unlike the previous study, a DNA damaging agent was not used to stabilize p53 for XPC upregulation in this study.
Previous reports indicate that XPC repair activity might be affected by genetic polymorphisms. For example, the XPC Lys939Gln variant may influence NER activity in irradiation-specific DNA repair (Vodicka et al., 2004) , and a coke oven worker with an XPC-PAT þ / þ (PAT is a biallelic polymorphism with an insertion of 83 bases of poly AT and a five bases deletion within intron 9 of XPC) genotype had higher BaP 7,8-dihydrodiol-9,10-epoxide (BPDE)-DNA adduct levels than those with XPC-PAT þ /À and XPC-PAT À/À genotypes (Pavanello et al., 2005) . However, our preliminary data did not show that either polymorphism influenced XPC gene expression, BPDE-like DNA adduct levels, or the occurrence of p53 mutations in lung cancer patients (data not shown). Thus, inactivation of XPC by promoter methylation might play a more important role than altered XPC repair activity during lung carcinogenesis. In our present study, XPC hypermethylation was observed in about 34% of all lung cancer tumors tested, with a higher prevalence in nonsmokers (41%) than in smokers (22%) ( Table 1) . Previous studies have shown that smokers with lung cancer or healthy controls tend to have more proficient DNA repair capacity than nonsmokers, suggesting that DNA repair capacity in smokers may be an adaptive response to DNA damage induced by chronic tobacco carcinogen exposure (Shen et al., 2003) . Among nonsmokers, it is likely that either an inadequate response of the DNA repair machinery to DNA damage or inaccurate repair contributes to the risk of developing lung cancer. Therefore, it is conceivable that XPC inactivation by hypermethylation may be, to a certain extent, responsible for the lower reduced DNA repair capability in lung cancer patients, especially in nonsmokers.
P16 (INK4a) hypermethylation has been associated with cigarette smoking in lung and bladder cancers (Kim et al., 2001; Soria et al., 2002; Toyooka et al., 2003a; Marsit et al., 2006) . In rodent model experiments, hypermethylation of the death-associated protein kinase was a frequent early event in tumor formation in A/J mice lung tumors induced by cigarette smoke, tobacco carcinogens, NNK and vinyl carbamate (Pulling et al., 2004) . In addition, a similar frequency of p16 hypermethylation was observed in smoking male lung cancer patients and nonsmoking female lung cancer patients with human papillomavirus 16 or 18 infections, respectively (Wu et al., 2005) . This is consistent with previous reports indicating that extensive promoter methylation of MGMT, hMLH1 (human mut-L homolouge1) and RASSF1A (Ras association domain family 1A) is associated with patients having both hepatocellular carcinoma and hepatitis viral infection (Matsukura et al., 2003; Schagdarsurengin et al., 2003) . These results suggest that promoter methylation of tumor suppressor genes is not only associated with cigarette smoking but also with viral infection during human carcinogenesis.
In this study, we observed lung cancer cell lines with XPC hypermethylation harbored mutated p53 (Figure 2) . Moreover, tumors from lung cancer patients with XPC hypermethylation were more likely to have a mutated p53 (Table 2) . Surprisingly, G-T mutation at codon 215 of p53 was detected in two independent XPC knockdown A549 cells after being treated with BaP for 60 days (15 passages) (Figure 3) . Consequently, abnormal p53 function was not only confirmed by a luciferase reporter assay (Figure 3c ), but also verified by downregulation of GADD45, Bax, p21 and mdm2 (data not shown). The p53 mutant S215I grows faster than the parental cells and shows higher percentage of cells in S-phase of cell cycle (25.6-35.2 versus 16.0%). This fastgrowing character might explain how the mutation be detected in XPC knockdown cells. It is worth noting that we also observed one patient with XPC hypermethylation who had the same mutational pattern. Interestingly, G-T mutation at codon 215 of p53 was also reported in hepatocellular carcinoma cell lines with hepatitis B virus X DNA and human papillomavirusimmortalized human bronchial epithelial (BEP2D) cells after treatment with a-particle or 1 GeV/nuleon 56 Fe particle (Kang et al., 1996; Piao et al., 1999) . Additionally, BEP2D cells harbored S215I of p53 mutant had more metastatic potential as compared with that of parental cells (Piao et al., 1999) . Our results are supported by previous report that p53 mutation was found in high passage human fibroblast cells (GM12995) derived from a XPC patient after treatment with UVC or g irradiation (Azzam et al., 2002) . These p53-mutated GM12995 cells showed deregulation in cell cycle control (Azzam et al., 2002) . In addition, it is well known that high susceptibility to UV-induced carcinogenesis was shown in mice lacking XPC gene (Sands et al., 1995) . In XPC mutant mice studies, a novel p53 hotspot mutation at codon 122 was found in UVinduced skin tumors (Inga et al., 2002; Nahari et al., 2004) . The predisposition to skin cancer in Xpc À/À mice is significantly enhanced by additional heterozygous mutations in the Trp53 gene (Xpc
) (Reis et al., 2000) . In this study, a p53 mutation at codon 215 was observed in two stable clones of XPC-inactivated lung cancer cells exposed to BaP. However, the molecular mechanism involved in Bap-induced p53 mutation in XPC-inactivated cells requires further investigation. This result strongly suggests that XPC inactivation may contribute to the occurrence of p53 mutation in lung cancer cells. Among lung cancer patients, p53 mutation frequency in lung cancer is generally higher in smokers than in nonsmokers (Gao et al., 2003; Toyooka et al., 2003b; Chang et al., 2005; Le Calvez et al., 2005) . However, there were no differences in the frequency of lung cancer patients presenting with p53 mutations between smokers and nonsmokers in the Taiwanese population used in this study; 34 of 94 (36%) nonsmokers versus 25 of 64 (39%) smokers with p53 mutation (P ¼ 0.712). This phenomenon might be explained by a higher frequency of XPC hypermethylation in nonsmokers than smokers in the study population (Table 1) .
MGMT inactivation through promoter hypermethylation was the first example of a repair gene whose expression correlated with a p53 mutation pattern (Esteller et al., 2000; Wolf et al., 2001; Zhang et al., 2003) . Mutation in p53 was shifted to a G-A mutation by MGMT promoter hypermethylation in colorectal cancer (Esteller et al., 2000) , and similar findings were later found for NSCLC (Wolf et al., 2001 ) and hepatocellular cancer (Zhang et al., 2003) . These mutations have been attributed to endogenous deamination of methylated cytosine to thymine. In this study, inactivation of XPC not only contributes to the occurrence of p53 mutation, but also enhances shifts in the p53 mutation pattern, especially G-T and G-C. On the other hand, numerous studies have explored the impact of p53 on MGMT gene expression but the findings were inconsistent (Nutt et al., 1999; Srivenugopal et al., 2001) . For example, after ionizing radiation, a higher MGMT expression level in various mouse fibroblasts and rat hepatoma cell lines with wild-type p53 gene was observed, as compared with that of mutant p53 gene, indicating that p53 may be involved in DNA damage-induced MGMT promoter activation (Nutt et al., 1999) . Inversely, MGMT transcription could be repressed by wild-type p53 protein in well-defined isogenic cell pairs (Srivenugopal et al., 2001) . Our preliminary data showed that XPC mRNA expression was repressed in p53 knockdown A549 cells compared with parental cells. Our preliminary data also showed that the acetylated histone 3 and histone 4 was decreased and binding activities of DNMT1 (DNA methyltransferase 1) on XPC promoter were increased in p53 knockdown A549 cells. These results suggest that wildtype p53 could be involved in chromatin remodeling to enhance XPC transcription. Thus, chromatin remodeling might be another mechanism to explain why XPC hypermethylation was frequently observed in lung cancer cells with p53 mutation. The detail mechanism should be further clarified.
To our knowledge, this is the first report to suggest that hypermethylation of the À175/À1 XPC promoter region plays an important role in XPC gene inactivation in lung cancer cell lines. We also showed that XPC hypermethylation is frequently observed in lung cancer cells with p53 mutation and in nonsmoking lung cancer patients. This hypermethylation may contribute to the occurrence of p53 mutations and to shifts in p53 mutation patterns leading to a higher incidence of G-T and G-C mutations. Therefore, XPC hypermethylation potentially enhances p53 mutation frequency, thereby promoting lung tumorigenesis.
Materials and methods
Cell lines
Human lung cancer cell lines A549, CH27, Calu-1, H1355, H23, H441, H661 and H1299 were obtained from American Type Culture Collection (Manassas, VA, USA). A pcDNA vector containing wild-type p53 cDNA (p53WT) was transient transfected into the p53 null H1299 cells. A549, Calu-1 and transfected H1299 were grown in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum at 371C in a 5% CO 2 atmosphere. CH27, H1355, H23, H441 and H661 were grown in Rosewell Park Memorial Institute medium-1640 supplemented with 5% fetal bovine serum at 371C in a 5% CO 2 atmosphere.
Construction of plasmids
To construct a wild-type XPC promoter-luciferase reporter plasmid, a 2.6-kb fragment of XPC (À2536/À1) PCR was amplified and cloned into the pGL3-Basic vector (Promega, Madison, WI, USA) to generate p2536. A series of XPC deletion mutants (p1174, p574, p385, p175) were constructed by amplifying the XPC promoter region with different primers. The sense primers were 5 5 0 -GCTTCC-CGCAGTTTTTTA-3 0 (À175), and the antisense primer was 5 0 -GTTGCTT-GTCTGGGCAAATTCCA CT-3 0 (À1). A KpnI site was incorporated into each sense primer and a BglII site into the anti-sense primer. After digestion of PCR products by KpnI and BglII (New England Biolabs, Beverly, MA, USA), fragments were cloned into the corresponding sites of the pGL3 plasmid followed by autosequencing (Applied Biosystems 3100 Avant Genetic Analyzer, Applied Biosystems/Hitachi, Japan) to confirm the constructs.
Cell transfection and luciferase reporter assay
To establish luciferase reporter assay, 1 mg of each XPC promoter deletion construct and 0.25 mg of b-galactosidase vector (pCH110) were co-transfected with pCDNA vector or pCDNA containing p53 gene (pCDNA-p53) into H1299 cells using Dioleoyltrimethylammoniumpropane (DOTAP) transfection reagent (Roche, Mannheim, Germany) according to the manufacturer's instructions. At 48 h after transfection, cells were washed twice with PBS and collected for luciferase assays. The relative luciferase activity was calculated by normalizing to both b-galactosidase and protein concentrations in each sample, and the data are means of triplicate relative luciferase activity values.
In vitro methylation of XPC promoter sequence The plasmid p175 was in vitro methylated by SssI methylase (New England Biolabs). The completeness of methylation was assessed by measuring the extent of protection from digestion by the restriction enzyme BstUI (New England Biolabs).
RNAi and BaP treatment
RNAi was performed by stable expressing of a small hairpin RNA (shRNA) to target XPC mRNA in A549 cell line. The shRNA template was constructed by two oligonucleotides with complementary sequence in loop region. The forward and reverse oligonucleotides containing 21 nucleotides of XPC are underlined, Forward primer: 5 0 -GATCCGCTCGAGATGAT GAGGAATTGTTCAAGAGAC-3 0 , Reverse primer: 5 0 -AGC TTAAAAAAGCTCGAGATGATGAGGAATTGTCTCTTG AAC-3 0 . The shRNA RNA template was cloned into pCDNA-HU6 vector as described in Chang (2004) . The XPC-specific shRNA contruct (3 mg) was then mixed with TransFast transfection reagent (Promega, Madison, WI, USA) and added to the A549 cells. Twenty-four hours after transfection, stable transfectants were selected in Gentamicin (Promega) at a concentration of 600 mg/ml. Thereafter, the selection medium was replaced every 3 days for a 3-week period. Interference of XPC was confirmed by Western-blot analysis. XPC RNAi clones were passaged at 1:10 dilution and continuously exposed to 1 mM BaP (Sigma-Aldrich Co., St Louis, MO, USA; stock solution: 1 mM, dissolved in dimethylsulfoxide (DMSO)) or 0.1% DMSO (solvent control).
Western-blot analysis A peptide spanning residues 741-940 and corresponding to the C terminus of XPC was used to produce a polyclonal antibody in a BALB/c mouse. Protein extraction and Western-blot analysis with chemiluminescent detection were as described by Emmert et al. (2000) . The following antibodies and dilution factors were used: mouse anti-XPC (1:3000), mouse-actin (H-196, Santa Cruz, Santa Cruz, CA, USA, 1:50 000) and antimouse peroxidase-conjugated immunoglobulin G (IgG-HRP, Santa Cruz, 1:5000).
Construction of mutant p53 S215I and pGL3-mdm2-p53 RE luc The coding region of p53 containing S215I mutation was PCR amplified and cloned into pDNA3.0 (Invitrogen Corp., Carlsbad, CA, USA). The pGL3-mdm2-p53 RE luc vector is a luciferase reporter construct regulated by mdm2 promoter containing p53 response element (Ko et al., 2002) .
Lung tumor specimens
Lung tumor specimens were collected from lung cancer patients at the Department of Thoracic Surgery, Taichung Veteran's General Hospital (TVGH), Taichung, Taiwan between 1992 and 2000 after obtaining written informed consent according to a biology study approved by the TVGH Institutional Review Board. A smoker was defined as someone who had smoked one cigarette or more per day for at least 1 year. Tumor types and stages were determined according to the WHO classification. p53 mutation analysis by direct sequencing Genomic DNA from lung cancer cell lines and lung tumor tissues was isolated by traditional proteinase K digestion and phenol-chloroform extraction. p53 mutation analyses were performed essentially as described by Ko et al. (2000) .
Methylation analysis by direct sequencing
Bisulfite treatment was performed according to previously described procedures (Herman et al., 1996) . A 275-bp fragment encompassing the 5 0 -end of the XPC gene (À175 to þ 100) (GenBank accession number AF261892) was amplified by PCR from bisulfite-treated DNA of lung cancer cell lines using the following primers: 5 0 -GTTTTTY(C/T) GTAGTTTTT TAGTGG-3 0 (sense) and 5 0 -CCTCCTCCTCC-TCCTCAC-3 0 (antisense). The PCR products were cloned into a TA vector (Yeastern Biotech, Taiwan) and sequenced by the Applied Biosystems PRISM dye terminator cycle sequencing method using reverse and forward M13 primers. At least three independent clones were examined.
Methylation analysis by HpaII-based PCR HpaII-based PCR was used to examine methylation of the 10th and 15th CpG islands within the À175/À1 XPC promoter sequence that contained the HpaII restriction endonuclease site (New England Biolabs). Briefly, the digested product was subjected to PCR amplification using a set of primers (5 0 -GCTTCCCGCAGTTTTTTA-3 0 and 5 0 -GTTGCTTGTCT GGGCAAATTCCAC-T-3 0 ). The PCR reaction was conducted under the following conditions: 941C for 5 min, 35 cycles of amplification (941C for 1 min, 541C for 1min and 721C for 1 min) and 721C for 10 min. The appearance of an amplified fragment of 175 bp indicated the presence of methylation.
Methylation analysis by MSP MSP was performed according to previously described procedures (Herman et al., 1996) . The methylation-sensitive primers were designed based on the sequencing data of the PCR-amplified bisulfite-modified tissue DNA. The methylated alleles were amplified using XPC-MSP-F (5 0 -AACGAA GGGGCGTGGTTAAGCG-3 0 ) and XPC-MSP-R (5 0 -TAAA CAAATTCCGCTTCCCGAATA-3 0 ). The PCR conditions were as follows: 941C for 5 min, 35 cycles of amplification (941C for 1 min, 601C for 1 min and 721C for 1 min) and 721C for 10 min. The unmethylated alleles were amplified using primers XPC-USP-F (5 0 -AATGAAGGGGTGTGGTTAAGT G-3 0 ) and XPC-USP-R (5 0 -TAAACAAATTCCACTTCC CAAATA-3 0 ) with similar PCR conditions.
Demethylation by 5-aza-2 0 -deoxycytidine Cells were seeded at a low density of 1 Â 10 5 /100-mm dish 16 h before the treatment with 1-10 mg/ml 5-aza-2 0 -deoxycytidine (5-aza-dC) (Sigma-Aldrich Co., St Louis, MO, USA) for 5 days. Treated and untreated cells from individual triplicate plates were harvested for analysis of their methylation status using the HpaII-based PCR assay and for analysis of XPC mRNA by RT-PCR.
Real-time polymerase chain reaction Total RNA was prepared from cell lines and lung tumor specimens using the TRIZOL reagent (Life Technologies, Grand Island, NY, USA). Expression levels of XPC were detected by PCR using the 18S rRNA gene as an internal control to indicate the amount of RNA in each reaction. The oligonucleotide sequences were as follows: for the XPC gene, sense, 5 0 -CCAGAGCAGGCGAAGACAAGA-3 0 , antisense, 5 0 -AAGCGGGCTGGGATG-ATGGAC-3 0 ; for the 18S rRNA gene, sense, 5 0 -TCGGAACTGAGGCCATGA-3 0 , antisense, 5 0 -CCGGTCGGCATCGTTTA-3 0 . The PCR conditions were as follows: 941C for 5 min, 35 cycles of amplification (941C for 1 min, 541C for 1 min and 721C for 1 min) and 721C for 10 min.
Immunohistochemistry
Tissue expression of XPC was determined with the streptavidin peroxidase method (LSAB Kit K675, Dako, USA) system. Negative controls lacked the primary antibody. Immunostaining results were assessed; the slides were assessed independently by three observers. XPC-positive tumor cell nuclei were evaluated by light microscopy. Patients were classified into either a positive group, with >10% positive cancer cells in the tissue, or a negative group, with o10% positive cancer cells.
Statistical analysis
Statistical analysis was performed using the SPSS statistical software program (Version 11.0 SPSS Inc., Chicago, IL, USA). The Student's t-test and Fisher's exact test (two-tailed) were used for statistical analyses.
